<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="[1]. Leishmania (Viannia) panamensis is an important causal agent of" exact="cutaneous leishmaniasis" post="(CL) in Central and South America [2] and approximately"/>
 <result pre="Leishmania (Viannia) panamensis is an important causal agent of cutaneous" exact="leishmaniasis" post="(CL) in Central and South America [2] and approximately"/>
 <result pre="and approximately 0.7-1.2 million cases occur annually. Different forms of" exact="leishmaniasis" post="demand expensive treatments, the currently used medicines pentavalent antimonials,"/>
 <result pre="treat CL [3]. In many tropical countries, the treatment of" exact="leishmaniasis" post="usually involves the oral administration of crude plant extracts"/>
 <result pre="Many studies related to the activity of plant extracts against" exact="leishmaniasis" post="have been reported [5]. Communities in the Andes have"/>
 <result pre="traditional uses and to develop new chemotherapeutic agents against this" exact="protozoal disease." post="Materials and Methods Ethical approval According to Colombian legislation,"/>
 <result pre="in Leishmaniasis Surveillance2017Retrieved on 20-05-2020Available from:http://www.who.int/leishmaniasis/resources/who_wer9238/en 3Fontenele-SilvaJ.SGalvaoT.FPereiraM.GSilvaM.TTreatment of American tegumentary" exact="leishmaniasis" post="in special populations:A summary of evidenceRev. Soc. Bras. Med."/>
</results>
